- Home
- SVRN vs XAIR Comparison
SVRN vs XAIR Comparison
Compare SVRN & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRN | XAIR |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | Greece | United States |
| Employees | 87 | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 10.1M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SVRN | XAIR |
|---|---|---|
| Price | $0.22 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 5.4M | 154.6K |
| Earning Date | 04-08-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,705,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 219.67 |
| 52 Week Low | $0.23 | $0.15 |
| 52 Week High | $1.47 | $3.78 |
Technical Indicators
Market Signals| Indicator | SVRN | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 29.61 | 36.65 |
| Support Level | N/A | $0.76 |
| Resistance Level | $0.84 | $1.25 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 5.15 | 22.84 |
Price Performance
Historical ComparisonAbout SVRN OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.